#United States #New York #Gross Law Firm #Sarepta Therapeutics #ELEVIDYS

The Gross Law Firm Files Class Action Lawsuit for Sarepta Therapeutics

In a significant development for investors, The Gross Law Firm has announced the initiation of a securities class action on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). This comes on the heels of troubling allegations surrounding the company's gene therapy product, ELEVIDYS, which are raising concerns about patient safety, adherence to regulatory protocols, and the overall credibility of company communications.

Understanding the Allegations

According to the complaint filed, shareholders who purchased shares during the class period from June 22, 2023, to June 24, 2025, are encouraged to take action. Allegations within the complaint claim that Sarepta Therapeutics made materially false statements or failed to disclose critical information regarding the safety of ELEVIDYS. This gene therapy, which is intended to treat Duchenne muscular dystrophy, is alleged to have significant safety risks that were not adequately reported or monitored during its clinical trials.

Key points of concern include:

1. Safety Risks: The product was said to pose significant safety risks to patients, which may not have been fully communicated to shareholders.
2. Failure in Trials: It was disclosed that trial regimes and protocols were insufficient in identifying severe side effects following the treatment, raising ethical and legal questions.
3. Regulatory Scrutiny: The severity of adverse events from the treatment could potentially lead to halts in recruitment and dosing processes within their trials, leading to greater scrutiny and risk for the company.
4. Misleading Statements: Overall, shareholders are alleging that they were misled by the company's positive projections that lacked reasonable basis given the information that was not disclosed.

How This Affects Shareholders

Shareholders who believe they have incurred losses during this period should act promptly. Registration for the class action lawsuit is being facilitated, and interested parties can find further details on how to register. The deadline to be appointed as a lead plaintiff for this case is August 25, 2025. However, it is important to note that a lead plaintiff designation is not required to be part of the recovery process.

Once an individual registers, they will be enrolled in a monitoring system that offers status updates throughout the litigation. The Gross Law Firm emphasizes that participation in this case comes with no fees or obligations, making it a risk-free opportunity for eligible shareholders.

Legal Perspective and Firm’s Mission

The Gross Law Firm has established itself as a key player in protecting investors' rights in cases of alleged corporate deceit and fraud. The firm is dedicated to advocating for responsible business practices and ensuring that shareholders are afforded justice in their financial dealings. Their role in this lawsuit is part of a broader mission to hold companies accountable for their actions.

For affected shareholders, this lawsuit could represent a critical chance at compensation and accountability from Sarepta Therapeutics, given the troubling nature of the allegations presented.

Conclusion

Investors of Sarepta Therapeutics, Inc. now have a platform to voice their concerns and seek redress from the purported negligence of the company. Those who purchased shares during the risky class period are urged to engage with The Gross Law Firm to secure their rights and potentially recover losses incurred due to misleading information and unsafe product practices. The Gross Law Firm stands ready to assist in this important legal battle for justice.